In vitro and in vivo activity of daptomycin plus ceftaroline for the treatment of experimental endocarditis due to Enterococcus faecalis with and without high-level aminoglycoside resistance
Journal of Antimicrobial Chemotherapy · 03.04.2026 · 81 (5)
DOI: 10.1093/jac/dkag136 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 22.04.2026. Verfasst von María-Alexandra Cañas und 17 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Clinic-Institut D'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Daptomycin, Enterococcus faecalis, Cephalosporins, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Instituto de Salud Carlos III, Ministerio de Economia y Competitividad, Pla estratègic de recerca i innovació en salut (PERIS).
Abstract (Originalsprache)
Objectives
Effective alternatives to standard of care treatment for E. faecalis infective endocarditis (EFIE) are needed. Some in vitro studies have suggested daptomycin and ceftaroline have synergistic activity against E. faecalis. We aimed to assess the in vitro and in vivo activity of daptomycin in combination with ceftaroline against E. faecalis clinical isolates with and without high-level of aminoglycoside resistance (HLAR). Materials and methods A panel of six endocarditis-associated E. faecalis isolates were used for time–kill assays at initial standard and high inocula. Daptomycin (10 mg/kg/day intravenously) and daptomycin (10 mg/kg/day iv) plus ceftaroline (600 mg q12 hours intravenous) were compared in vivo using a human-like pharmacokinetic model in two treatment groups using the experimental EFIE model in rabbits.
Results
The combination of daptomycin plus ceftaroline achieved synergy against all three HLAR and all three non-HLAR strains in time–kill assays at initial standard inoculum. A bactericidal effect was observed in two of the three HLAR E. faecalis isolates. For HLAR EFAE-188, the use of daptomycin plus ceftaroline significantly decreased the bacterial density in vegetations compared with daptomycin alone (median density 5.2 versus 6.7 log10 cfu/g; P = 0.028). For non-HLAR EFAE-468, the bacterial density in vegetations was lower with the combination therapy than with daptomycin alone (median density 5.2 versus 6.8 log10 cfu/g; P = 0.072). Adding ceftaroline prevented the development of daptomycin-resistant E. faecalis isolates in all cases.
Conclusions
Daptomycin plus ceftaroline represents a promising alternative for treating EFIE. Further clinical studies are needed to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hospital Clinic-Institut D'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
- Infectious Diseases Department, Pontchaillou University Hospital, Rennes, France.
- Inserm U1230 BRM, Rennes University Hospital, Rennes, France.
- CIBER of Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
- Biomedical Research Networking Center of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, Madrid, Spain.
- Microbiology, Genetics and Statistics Department, University of Barcelona, Barcelona, Spain.
ORCID-Profile: María-Alexandra Cañas, David Luque-Paz, Cristina García-De-La-Mària, José M Miró
Förderung
- Instituto de Salud Carlos III
- Ministerio de Economia y Competitividad
- Pla estratègic de recerca i innovació en salut (PERIS)
- Institut d'Investigacions Biomèdiques August Pi i Sunyer
- European Regional Development Fund
- RICAI International Mobility
- Rennes University Hospital International Mobility
- Collège Doctoral de Bretagne Outgoing International Mobility Programme
Zitieren
APA
Cañas, M. A., García-González, J., Luque-Paz, D., Cuervo, G., Krivak, F., Nin-Blanch, J., Hernández-Meneses, M., Falces, C., Maristany, M., Perissinotti, A., Vidal, B., Tolosana, J. M., Quintana, E., Llopis, J., Moreno, A., García-De-La-Mària, C., Miró, J. M., & Hospital Clinic Endocarditis Study Group (2026). In vitro and in vivo activity of daptomycin plus ceftaroline for the treatment of experimental endocarditis due to Enterococcus faecalis with and without high-level aminoglycoside resistance. Journal of Antimicrobial Chemotherapy, 81(5). https://doi.org/10.1093/jac/dkag136
Vancouver
Cañas MA, García-González J, Luque-Paz D, Cuervo G, Krivak F, Nin-Blanch J, et al. In vitro and in vivo activity of daptomycin plus ceftaroline for the treatment of experimental endocarditis due to Enterococcus faecalis with and without high-level aminoglycoside resistance. Journal of Antimicrobial Chemotherapy. 2026;81(5). doi:10.1093/jac/dkag136
BibTeX
@article{Caas2026,
author = {Cañas, María-Alexandra and García-González, Javier and Luque-Paz, David and Cuervo, Guillermo and Krivak, Filip and Nin-Blanch, Judit and Hernández-Meneses, Marta and Falces, Carles and Maristany, Marta and Perissinotti, Andres and Vidal, Bàrbara and Tolosana, José María and Quintana, Eduard and Llopis, Jaume and Moreno, Asunción and García-De-La-Mària, Cristina and Miró, José M and Hospital Clinic Endocarditis Study Group, Hospital Clinic Endocarditis Study Group},
title = {In vitro and in vivo activity of daptomycin plus ceftaroline for the treatment of experimental endocarditis due to Enterococcus faecalis with and without high-level aminoglycoside resistance},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
volume = {81},
number = {5},
doi = {10.1093/jac/dkag136}
}
EUVIMED